Profound Medical (PROF) Projected to Announce Quarterly Earnings on Thursday

Key Points

• Profound Medical is expected to report Q3 2026 results on November 5 after market close, with analysts forecasting a loss of $0.192 per share and revenue of $8.82 million.
• The company’s previous quarter fell short of expectations, reporting a $0.26 per-share loss and $2.48 million in revenue versus the $4.75 million consensus estimate.
• PROF shares opened at $5.78, while analyst sentiment remains mixed but leans positive: the stock has a “Moderate Buy” consensus rating and an $11.50 average price target.

Profound Medical (NASDAQ:PROF - Get Free Report) is projected to issue its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.1920) per share and revenue of $8.82 million for the quarter. Individuals may review the information on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Profound Medical (NASDAQ:PROF - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.04). Profound Medical had a negative return on equity of 63.03% and a negative net margin of 171.57%. The firm had revenue of $2.48 million during the quarter, compared to analysts' expectations of $4.75 million. On average, analysts expect Profound Medical to post ($0.79) EPS for the current fiscal year and ($0.48) EPS for the next fiscal year.

Profound Medical Stock Performance

PROF stock opened at $5.78 on Thursday. Profound Medical has a fifty-two week low of $4.80 and a fifty-two week high of $8.95. The company has a market cap of $211.32 million, a price-to-earnings ratio of -5.90 and a beta of 0.75. The business's 50-day moving average is $6.25 and its two-hundred day moving average is $6.71.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Weiss Ratings downgraded shares of Profound Medical from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, October 23rd. Raymond James Financial raised Profound Medical from an "outperform" rating to a "strong-buy" rating and set a $11.00 price target for the company in a report on Monday, July 27th. Finally, Wall Street Zen upgraded Profound Medical from a "sell" rating to a "hold" rating in a research report on Saturday, October 10th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Profound Medical presently has an average rating of "Moderate Buy" and a consensus price target of $11.50.

About Profound Medical

Profound Medical Corp. is a medical-technology company focused on developing and commercializing minimally invasive, incision-free treatments for prostate disease. The company's flagship platform, TULSA-PRO, combines magnetic resonance imaging (MRI) with robotic-controlled transurethral ultrasound to ablate targeted prostate tissue while enabling physicians to monitor treatment in real time.

TULSA-PRO is primarily used for the treatment of localized prostate cancer and other prostate conditions, including benign prostatic hyperplasia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.